Results 251 to 260 of about 257,826 (338)

Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma [PDF]

, 2017
Bartlett, Nancy L, et al,, Ghobadi, Armin   +2 more
core   +2 more sources

A critical review of management of allogeneic transplant‐eligible adults with Ph+ acute lymphoblastic leukaemia

British Journal of Haematology, EarlyView.
Proposed management of newly diagnosed Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukaemia (ALL) in transplant‐eligible patients. Suggested considerations when deciding the treatment pathway available to a newly diagnosed Ph+ ALL patient that would be deemed transplant eligible. Summary Acute lymphoblastic leukaemia (ALL) in 20%–30% of
Naranie Shanmuganathan, Andrew Grigg
wiley   +1 more source

Chrysin mitigates cyclophosphamide-triggered cardiotoxicity in rats: Insights into cardioprotection via Treg expression modulation and iNOS downregulation. [PDF]

Toxicol Rep
Saleh DO, Elbaset MA, Ahmed KA, Sedik AA.   +3 more
europepmc   +1 more source

A Review of Cyclophosphamide [PDF]

British Journal of Cancer, 1975
openaire   +2 more sources

Drug development and testing in relation to cell migration and chimerism [PDF]

, 1993
Demetris, AJ, Giorda, R, Murase, N, Starzl, TE, Trucco, M, Valdivia, L   +5 more
core  

Long‐term outcome after allogeneic stem cell transplantation for GATA2 deficiency: An analysis of 67 adults and children from France and Belgium

British Journal of Haematology, EarlyView.
The overall survival of patients receiving an allogeneic haematopoietic stem cell transplant (HSCT) for GATA2 deficiency was significantly better if they were transplanted recently, with a bone marrow or cord blood graft and if the transplant was performed before the onset of excess blast. Excess blast before HSCT was the only factor associated with an
Flore Sicre de Fontbrune, Florian Chevillon, Mony Fahd, Kristell Desseaux, Xavier Poiré, Edouard Forcade, Arthur Sterin, Bénédicte Neven, Virginie Gandemer, Sylvain Thepot, Alice Garnier, Bruno Lioure, Ambroise Marcais, Stephanie Nguyen‐Quoc, Suzanne Tavitian, Laure Vincent, Jean Donadieu, Matthieu Resche Riggon, Sylvie Chevret, Marlene Pasquet, Regis Peffault de Latour   +20 more
wiley   +1 more source

Enterocolitis associated with glofitamab—First report and clinicopathological findings in three cases

British Journal of Haematology, EarlyView.
Summary Glofitamab is a CD3‐CD20 bispecific antibody used to treat B‐cell non‐Hodgkin lymphoma. We describe three cases of enterocolitis occurring with glofitamab at a single institution. Similarities between cases include onset post cycle 4–5, moderately elevated faecal calprotectin, abnormal bowel avidity on positron emission tomography scan (2/3 ...
Sean McKeague, Molly Robertson, Sam van der Linde, Christine Khoo, Jonathan Segal, Sean Harrop, Adrian Minson, Andrew W. Roberts, Michael Dickinson   +8 more
wiley   +1 more source

Biopsy-Confirmed Small Vessel Primary CNS Vasculitis: Clinical Features and Impact of Early Intensive Treatment on Remission. [PDF]

Neurol Neuroimmunol Neuroinflamm
Reddy SP, LaHue SC, Goglin S, Chung SA, Poole S, Bove R, Pekmezci M, Tihan T, Gelfand JM.   +8 more
europepmc   +1 more source

How we manage immune‐mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance

British Journal of Haematology, EarlyView.
The use of rituximab as a pre‐emptive treatment in immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is the current standard of care. However, for patients refractory to rituximab or for those with contraindication, further treatment guidelines are scarce.
Julia Weisinger, Jehane Fadlallah, Bérangère Joly, Agnès Veyradier, Paul Coppo   +4 more
wiley   +1 more source